All
Study links cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.
Comparing vorolanib intravitreal insert with aflibercept in DME treatment
EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.
Enrollment complete for Beacon Therapeutics' phase 2/3 VISTA trial
The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.
Reducing site burden and expanding research capacity with AI
How artificial intelligence could enhance clinical trials.
Exposure to pesticides and increased risk of AMD
A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.
A review of the DAVIO 2 phase 2 trial results
A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Phase 3 PHOENIX trial for oral GA treatment completes enrollment
Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing Tinlarebant's potential to treat geographic atrophy.
Multiple intravitreal injections and their effect on the optic nerve head in patients with CRVO
Research from the iMIND lab at Duke University.
THULITE phase II study evaluates BI 1815368
Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.
Highlights from ARVO 2025
Retinal imaging and the future of early Alzheimer diagnosis.
Intravitreal implant shows potential for treating the root causes of glaucoma and diabetic retinopathy
New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.
Retina roundup: June 30 to July 4
Catch up on this week's highlights in retina.
Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME
The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.
Improving retinal drying and treatment durability with second-generation anti-VEGF therapies
Recapping a recent conversation led by Dilsher S. Dhoot, MD.
Most patients support AI in healthcare if it means more time with doctors
Patients express mixed feelings about AI in healthcare, favoring its use for documentation and administrative tasks while demanding transparency and safety standards.
The future promise of advanced therapies in ophthalmology
Cell and gene therapies in development for unmet needs.
Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program
Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.
Nanoscope announces formation of Vision Advisory Committee
Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.
Retina roundup: June 23 to June 27
CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changes
Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.
Advancing ocular pharmacotherapy through the suprachoroidal space
Insights on injection technique and the future potential of SCS treatments.
Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001
PYC works to meet FDA alignment for its investigational drug candidate, VP-001
PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.
Successful phase 1B study of oral therapy for diabetic retinopathy
Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.
How remote retinal imaging raises the bar across service, research and education
Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.
Pearls for engaging in clinical trials
Make the most of your practice and your retina conference participation.
Q&A: Meeting the need for low vision services with wearable tech
Innovative assistive devices empower patients with central vision loss to regain independence and enhance daily activities, transforming their quality of life.
